Abstract: Methods of detecting, predicting severity of, and/or predicting treatment response to respiratory virus infection in a sample obtained from a subject. The methods include assaying a methylation state of a marker in a sample obtained from a subject and identifying the subject as having respiratory virus infection, a likelihood of severe outcomes of respiratory infection, and/or a likelihood of treatment response depending on the methylation state of the marker. The markers can include bases (DMP) in differentially methylated regions (DMR) as provided herein.

Abstract: The present invention relates to methods of identifying, collecting and isolating pluripotent stem cells, and compositions of purified stem cells for the diagnosis of susceptibility to drug induced myopathy (DIM) and malignant hyperthermia (MH). Specifically, the present invention provides methods of producing skeletal muscle myocytes from patient-specific stem cells, and methods for identifying susceptibility to DIM and MH in patient-specific skeletal muscle myocytes generated from patient-specific stem cells. The present invention also relates to methods, compositions and kits for screening drugs for DIM and MH risk.

Abstract: A method for detection of susceptibility to nitrous oxide neurologic syndrome in a subject is disclosed. In one embodiment, the method comprises: (a) providing a sample from a subject, wherein said subject is a candidate for nitrous oxide anesthesia; and (b) detecting the presence or absence of folate, cobalamin, methionine and homocysteine pathway genetic polymorphisms in said sample, wherein the presence of a polymorphism indicates that the subject is susceptible to nitrous oxide neurologic syndrome.

Abstract: The present invention relates generally to the field of methods useful in treating tissue injury. More specifically, the present invention relates to (6S)-5-methyltetrahydrofolic acid compounds, and methods of using the (6S)-5-methyltetrahydrofolic acid compounds, to treat conditions associated with nervous system injury.

Abstract: A method of assaying nucleotide receptor P2X7 pore activity in white blood cells contained within a mixed cell sample is provided comprising labeling white blood cells with a white blood cell-specific label; depolarizing the labeled white blood cells with an isotonic depolarizing solution; contacting the labeled white blood cells with dye and a P2X7 agonist in an amount sufficient to activate P2X7 pore activity; contacting the labeled white blood cells with a divalent cation in an amount sufficient to deactivate P2X7 pore activity; and analyzing dye uptake whereby P2X7 pore activity is quantified by the amount of dye taken up in labeled white blood cells treated with the P2X7 agonist relative to labeled white blood cells in the absence of said P2X7 agonist, said P2X7 pore activity being corrected for sample age and by subtraction of P2X7 pore activity contributed by nonviable white blood cells.

Abstract: The present invention relates to recovery from anesthesia. In particular, the present invention relates to systems, compositions and methods of monitoring and assessing recovery of cognitive function in subjects undergoing surgical and medical procedures requiring anesthesia and sedation.

Abstract: A method of rapidly assaying nucleotide receptor P2X7 pore activity in white blood cells contained within a blood sample. A method according to the invention includes the steps of: (a) labeling the white blood cells with a white blood cell-specific label; (b) depolarizing the labeled white blood cells with an isotonic depolarizing solution; (c) contacting the labeled white blood cells with a dye and a P2X7 agonist in an amount sufficient to activate nucleotide receptor P2X7 pore activity; (d) contacting the labeled white blood cells with a divalent cation in an amount sufficient to deactivate nucleotide receptor P2X7 pore activity; and (e) analyzing dye uptake in labeled white blood cells whereby nucleotide receptor P2X7 pore activity is quantified by the amount of dye taken up in labeled white blood cells treated with P2X7 agonist relative to labeled white blood cells in the absence of P2X7 agonist.

Abstract: A method of assaying nucleotide receptor P2X7 pore activity in white blood cells contained within a mixed cell sample is provided comprising labeling white blood cells with a white blood cell-specific label; depolarizing the labeled white blood cells with an isotonic depolarizing solution; contacting the labeled white blood cells with dye and a P2X7 agonist in an amount sufficient to activate P2X7 pore activity; contacting the labeled white blood cells with a divalent cation in an amount sufficient to deactivate P2X7 pore activity; and analyzing dye uptake whereby P2X7 pore activity is quantified by the amount of dye taken up in labeled white blood cells treated with the P2X7 agonist relative to labeled white blood cells in the absence of said P2X7 agonist, said P2X7 pore activity being corrected for sample age and by subtraction of P2X7 pore activity contributed by nonviable white blood cells.

Abstract: A method of rapidly assaying nucleotide receptor P2X7 pore activity in white blood cells contained within a blood sample. A method according to the invention includes the steps of: (a) labeling the white blood cells with a white blood cell-specific label; (b) depolarizing the labeled white blood cells with an isotonic depolarizing solution; (c) contacting the labeled white blood cells with a dye and a P2X7 agonist in an amount sufficient to activate nucleotide receptor P2X7 pore activity; (d) contacting the labeled white blood cells with a divalent cation in an amount sufficient to deactivate nucleotide receptor P2X7 pore activity; and (e) analyzing dye uptake in labeled white blood cells whereby nucleotide receptor P2X7 pore activity is quantified by the amount of dye taken up in labeled white blood cells treated with P2X7 agonist relative to labeled white blood cells in the absence of P2X7 agonist.

Abstract: A method of determining whether a canine is susceptible to canine malignant hyperthermia is disclosed. In one embodiment, this method comprises the step of obtaining a nucleic acid sample from a canine and examining the DNA sample for the presence or absence of a T1640C mutation, wherein the presence of the mutation indicates that the canine is susceptible to canine malignant hyperthermia.

Abstract: A method of determining whether a canine is susceptible to canine malignant hyperthermia is disclosed. In one embodiment, this method comprises the step of obtaining a nucleic acid sample from a canine and examining the DNA sample for the presence or absence of a T1640C mutation, wherein the presence of the mutation indicates that the canine is susceptible to canine malignant hyperthermia.

Abstract: A method for detection of susceptibility to nitrous oxide neurologic syndrome in a subject is disclosed. In one embodiment, the method comprises: (a) providing a sample from a subject, wherein said subject is a candidate for nitrous oxide anesthesia; and (b) detecting the presence or absence of folate, cobalamin, methionine and homocysteine pathway genetic polymorphisms in said sample, wherein the presence of a polymorphism indicates that the subject is susceptible to nitrous oxide neurologic syndrome.

Abstract: A method of determining whether a canine is susceptible to canine malignant hyperthermia is disclosed. In one embodiment, this method comprises the step of obtaining a nucleic acid sample from a canine and examining the DNA sample for the presence or absence of a T1640C mutation, wherein the presence of the mutation indicates that the canine is susceptible to canine malignant hyperthermia.